Skip to main content
Top
Published in: Annals of Surgical Oncology 9/2019

01-09-2019 | Nephrectomy | Urologic Oncology

The CANLPH Score, an Integrative Model of Systemic Inflammation and Nutrition Status (SINS), Predicts Clinical Outcomes After Surgery in Renal Cell Carcinoma: Data From a Multicenter Cohort in Japan

Authors: Kazumasa Komura, MD, PhD, Takeshi Hashimoto, MD, PhD, Takuya Tsujino, MD, Ryu Muraoka, MD, Takeshi Tsutsumi, MD, Naoya Satake, MD, PhD, Tomohisa Matsunaga, MD, Yuki Yoshikawa, MD, Tomoaki Takai, MD, PhD, Koichiro Minami, MD, PhD, Kohei Taniguchi, MD, PhD, Hirofumi Uehara, MD, Tomohito Tanaka, MD, PhD, Hajime Hirano, MD, PhD, Hayahito Nomi, MD, PhD, Naokazu Ibuki, MD, PhD, Kiyoshi Takahara, MD, PhD, Teruo Inamoto, MD, PhD, Yoshio Ohno, MD, PhD, Haruhito Azuma, MD, PhD

Published in: Annals of Surgical Oncology | Issue 9/2019

Login to get access

Abstract

Background

A myriad of studies have demonstrated the clinical association of systemic inflammatory and nutrition status (SINS) including C-reactive protein/albumin ratio (CAR), the neutrophil/lymphocyte ratio (NLR), and the platelet/hemoglobin ratio (PHR). This study aimed to investigate the predictive value of the score integrating these variables (CANLPH) in patients with renal cell carcinoma (RCC).

Methods

Using cohort data from a multi-institutional study, 757 of 1109 patients were retrospectively analyzed. The optimal cutoff value for outcome prediction of continuous variables in CAR, NLR, and PHR was determined and the CANLPH score was then calculated as the sum score of 0 or 1 by the cutoff value in each ratio.

Results

The median follow-up time was 76 months for the patients who survived (n = 585) and 31 months for those who died (n = 172). The Youden Index offered an optimal cutoff of 1.5 for CAR and 2.8 for NLR, and a higher value from the cutoff was assigned as a score of 1. The cutoff value of the PHR was defined as 2.1 for males and 2.3 for females. The patients were assigned a CANLPH score of 0 (47.2%), 1 (31.3%), 2 (13.1%), or 3 (8.5%). In the multivariate analysis, the CANLPH score served as an independent predictor of cancer-specific mortality in both localized and metastatic RCC.

Conclusion

The score was well-correlated with clinical outcome for the RCC patients. Because this score can be concisely measured at the point of diagnosis, physicians may be encouraged to incorporate this model into the treatment for RCC.
Literature
1.
2.
go back to reference Albiges L, Hakimi AA, Xie W et al. (2016) Body mass index and metastatic renal cell carcinoma: clinical and biological correlations. J Clin Oncol. 34:3655–63.CrossRefPubMedPubMedCentral Albiges L, Hakimi AA, Xie W et al. (2016) Body mass index and metastatic renal cell carcinoma: clinical and biological correlations. J Clin Oncol. 34:3655–63.CrossRefPubMedPubMedCentral
3.
go back to reference Byun SS, Hwang EC, Kang SH, et al. (2018) Age-dependent prognostic value of body mass index for non-metastatic clear cell renal cell carcinoma: a large multicenter retrospective analysis. J Surg Oncol. 118:199–205.CrossRefPubMed Byun SS, Hwang EC, Kang SH, et al. (2018) Age-dependent prognostic value of body mass index for non-metastatic clear cell renal cell carcinoma: a large multicenter retrospective analysis. J Surg Oncol. 118:199–205.CrossRefPubMed
4.
go back to reference Komura K, Inamoto T, Black PC, et al. (2011) Prognostic significance of body mass index in Asian patients with localized renal cell carcinoma. Nutr Cancer. 63:908–15.CrossRefPubMed Komura K, Inamoto T, Black PC, et al. (2011) Prognostic significance of body mass index in Asian patients with localized renal cell carcinoma. Nutr Cancer. 63:908–15.CrossRefPubMed
5.
go back to reference Ramsey S (2009) The role of the systemic inflammatory response as a biomarker in immunotherapy for renal cell cancer. Mol Diagn Ther. 13:277–81.CrossRefPubMed Ramsey S (2009) The role of the systemic inflammatory response as a biomarker in immunotherapy for renal cell cancer. Mol Diagn Ther. 13:277–81.CrossRefPubMed
6.
go back to reference Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 371:569–78.CrossRefPubMed Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 371:569–78.CrossRefPubMed
7.
go back to reference Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B (2000) Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 343:1305–11.CrossRefPubMed Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B (2000) Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 343:1305–11.CrossRefPubMed
8.
go back to reference Ohno Y (2018) Role of systemic inflammatory response markers in urological malignancy. Int J Urol. 28:31–47.CrossRef Ohno Y (2018) Role of systemic inflammatory response markers in urological malignancy. Int J Urol. 28:31–47.CrossRef
9.
go back to reference Viers BR, Houston Thompson R, Boorjian SA, Lohse CM, Leibovich BC, Tollefson MK (2014) Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy. Urol Oncol. 32:1277–84.CrossRefPubMed Viers BR, Houston Thompson R, Boorjian SA, Lohse CM, Leibovich BC, Tollefson MK (2014) Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy. Urol Oncol. 32:1277–84.CrossRefPubMed
10.
go back to reference Keizman D, Ish-Shalom M, Huang P, et al. (2012) The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival, and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer. 48:202–8.CrossRefPubMed Keizman D, Ish-Shalom M, Huang P, et al. (2012) The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival, and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer. 48:202–8.CrossRefPubMed
11.
go back to reference Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M (2010) Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol. 184:873–8.CrossRefPubMed Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M (2010) Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol. 184:873–8.CrossRefPubMed
12.
go back to reference Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC (2007) Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer. 109:205–12.CrossRefPubMed Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC (2007) Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer. 109:205–12.CrossRefPubMed
13.
go back to reference Hutterer GC, Krieger D, Mrsic E, et al. (2015) Preoperative leucocytosis, thrombocytosis, and anemia as potential prognostic factors in non-metastatic renal cell carcinoma. Anticancer Res. 35:3463–9.PubMed Hutterer GC, Krieger D, Mrsic E, et al. (2015) Preoperative leucocytosis, thrombocytosis, and anemia as potential prognostic factors in non-metastatic renal cell carcinoma. Anticancer Res. 35:3463–9.PubMed
14.
go back to reference World Medical A (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 310:2191–4.CrossRef World Medical A (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 310:2191–4.CrossRef
15.
go back to reference Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 6:655–63.CrossRefPubMed Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 6:655–63.CrossRefPubMed
16.
go back to reference Zisman A, Pantuck AJ, Wieder J, et al. (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 20:4559–66.CrossRefPubMed Zisman A, Pantuck AJ, Wieder J, et al. (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 20:4559–66.CrossRefPubMed
17.
go back to reference McMillan DC (2008) An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 67:257–62.CrossRefPubMed McMillan DC (2008) An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 67:257–62.CrossRefPubMed
20.
go back to reference Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 15:361–87.CrossRefPubMed Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 15:361–87.CrossRefPubMed
21.
go back to reference Aron M, Nguyen MM, Stein RJ, Gill IS (2008) Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur Urol. 54:133–40.CrossRefPubMed Aron M, Nguyen MM, Stein RJ, Gill IS (2008) Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur Urol. 54:133–40.CrossRefPubMed
22.
go back to reference May M, Aziz A, Zigeuner R, et al. (2013) Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: an analysis of the multicenter CORONA database. World J Urol. 31:1073–80.CrossRefPubMed May M, Aziz A, Zigeuner R, et al. (2013) Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: an analysis of the multicenter CORONA database. World J Urol. 31:1073–80.CrossRefPubMed
23.
go back to reference Lamb GW, Aitchison M, Ramsey S, Housley SL, McMillan DC (2012) Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems. Br J Cancer. 106:279–83.CrossRefPubMed Lamb GW, Aitchison M, Ramsey S, Housley SL, McMillan DC (2012) Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems. Br J Cancer. 106:279–83.CrossRefPubMed
24.
go back to reference Cho DS, Kim SI, Choo SH, Jang SH, Ahn HS, Kim SJ (2016) Prognostic significance of modified Glasgow Prognostic Score in patients with non-metastatic clear cell renal cell carcinoma. Scand J Urol. 50:186–91.CrossRefPubMed Cho DS, Kim SI, Choo SH, Jang SH, Ahn HS, Kim SJ (2016) Prognostic significance of modified Glasgow Prognostic Score in patients with non-metastatic clear cell renal cell carcinoma. Scand J Urol. 50:186–91.CrossRefPubMed
25.
go back to reference Tsujino T, Komura K, Matsunaga T, et al. (2017) Preoperative measurement of the Modified Glasgow Prognostic Score predicts patient survival in non-metastatic renal cell carcinoma prior to nephrectomy. Ann Surg Oncol. 24:2787–93.CrossRefPubMed Tsujino T, Komura K, Matsunaga T, et al. (2017) Preoperative measurement of the Modified Glasgow Prognostic Score predicts patient survival in non-metastatic renal cell carcinoma prior to nephrectomy. Ann Surg Oncol. 24:2787–93.CrossRefPubMed
26.
go back to reference Inamoto T, Matsuyama H, Sakano S, et al. (2017) The systemic inflammation-based Glasgow Prognostic Score as a powerful prognostic factor in patients with upper tract urothelial carcinoma. Oncotarget. 8:113248–57.CrossRefPubMedPubMedCentral Inamoto T, Matsuyama H, Sakano S, et al. (2017) The systemic inflammation-based Glasgow Prognostic Score as a powerful prognostic factor in patients with upper tract urothelial carcinoma. Oncotarget. 8:113248–57.CrossRefPubMedPubMedCentral
27.
go back to reference Liu Z, Jin K, Guo M, et al. (2017) Prognostic value of the CRP/Alb ratio, a novel inflammation-based score in pancreatic cancer. Ann Surg Oncol. 24:561–8.CrossRefPubMed Liu Z, Jin K, Guo M, et al. (2017) Prognostic value of the CRP/Alb ratio, a novel inflammation-based score in pancreatic cancer. Ann Surg Oncol. 24:561–8.CrossRefPubMed
28.
go back to reference Guo S, He X, Chen Q, et al. (2017) The C-reactive protein/albumin ratio, a validated prognostic score, predicts outcome of surgical renal cell carcinoma patients. BMC Cancer. 17:171.CrossRefPubMedPubMedCentral Guo S, He X, Chen Q, et al. (2017) The C-reactive protein/albumin ratio, a validated prognostic score, predicts outcome of surgical renal cell carcinoma patients. BMC Cancer. 17:171.CrossRefPubMedPubMedCentral
29.
go back to reference Zhang H, Zhang L, Zhu K, et al. (2015) Prognostic significance of combination of preoperative platelet count and neutrophil-lymphocyte ratio (COP-NLR) in patients with non-small cell lung cancer: based on a large cohort study. PLoS One. 10:e0126496.CrossRefPubMedPubMedCentral Zhang H, Zhang L, Zhu K, et al. (2015) Prognostic significance of combination of preoperative platelet count and neutrophil-lymphocyte ratio (COP-NLR) in patients with non-small cell lung cancer: based on a large cohort study. PLoS One. 10:e0126496.CrossRefPubMedPubMedCentral
30.
go back to reference Lin YH, Chang KP, Lin YS, Chang TS (2017) Pretreatment combination of platelet counts and neutrophil-lymphocyte ratio predicts survival of nasopharyngeal cancer patients receiving intensity-modulated radiotherapy. Onco Targets Ther. 10:2751–60.CrossRefPubMedPubMedCentral Lin YH, Chang KP, Lin YS, Chang TS (2017) Pretreatment combination of platelet counts and neutrophil-lymphocyte ratio predicts survival of nasopharyngeal cancer patients receiving intensity-modulated radiotherapy. Onco Targets Ther. 10:2751–60.CrossRefPubMedPubMedCentral
31.
go back to reference Tsujino T, Komura K, Ichihashi A, et al. (2017) The combination of preoperative platelet count and neutrophil-lymphocyte ratio as a prognostic indicator in localized renal cell carcinoma. Oncotarget. 8:110311–25.CrossRefPubMedPubMedCentral Tsujino T, Komura K, Ichihashi A, et al. (2017) The combination of preoperative platelet count and neutrophil-lymphocyte ratio as a prognostic indicator in localized renal cell carcinoma. Oncotarget. 8:110311–25.CrossRefPubMedPubMedCentral
32.
go back to reference Sakamoto T, Saito H, Uchinaka EI, et al. (2018) The combination of neutrophil-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic indicator in patients with recurrent pancreatic cancer. Anticancer Res. 38:5497–503.CrossRefPubMed Sakamoto T, Saito H, Uchinaka EI, et al. (2018) The combination of neutrophil-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic indicator in patients with recurrent pancreatic cancer. Anticancer Res. 38:5497–503.CrossRefPubMed
33.
go back to reference Cheng H, Luo G, Lu Y, et al. (2016) The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. Pancreatology. 16:1080–4.CrossRefPubMed Cheng H, Luo G, Lu Y, et al. (2016) The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. Pancreatology. 16:1080–4.CrossRefPubMed
34.
go back to reference Huang Z, Liu Y, Yang C, et al. (2018) Combined neutrophil/platelet/lymphocyte/differentiation score predicts chemosensitivity in advanced gastric cancer. BMC Cancer. 18:515.CrossRefPubMedPubMedCentral Huang Z, Liu Y, Yang C, et al. (2018) Combined neutrophil/platelet/lymphocyte/differentiation score predicts chemosensitivity in advanced gastric cancer. BMC Cancer. 18:515.CrossRefPubMedPubMedCentral
35.
go back to reference Chen YP, Chen C, Mai ZY, et al. (2015) Pretreatment platelet count as a predictor for survival and distant metastasis in nasopharyngeal carcinoma patients. Oncol Lett. 9:1458–66.CrossRefPubMedPubMedCentral Chen YP, Chen C, Mai ZY, et al. (2015) Pretreatment platelet count as a predictor for survival and distant metastasis in nasopharyngeal carcinoma patients. Oncol Lett. 9:1458–66.CrossRefPubMedPubMedCentral
36.
go back to reference Chen S, Na N, Jian Z (2018) Pretreatment platelet count as a prognostic factor in patients with pancreatic cancer: a systematic review and meta-analysis. Onco Targets Ther. 11:59–65.CrossRefPubMed Chen S, Na N, Jian Z (2018) Pretreatment platelet count as a prognostic factor in patients with pancreatic cancer: a systematic review and meta-analysis. Onco Targets Ther. 11:59–65.CrossRefPubMed
37.
go back to reference Tang G, Zhen Y, Xie W, et al. (2018) Preoperative hemoglobin-platelet ratio can significantly predict progression and mortality outcomes in patients with T1G3 bladder cancer undergoing transurethral resection of bladder tumor. Oncotarget. 9:18627–36.PubMedPubMedCentral Tang G, Zhen Y, Xie W, et al. (2018) Preoperative hemoglobin-platelet ratio can significantly predict progression and mortality outcomes in patients with T1G3 bladder cancer undergoing transurethral resection of bladder tumor. Oncotarget. 9:18627–36.PubMedPubMedCentral
38.
go back to reference Li X, Xing Y-F, Lin Z-H, et al. Platelet-to-hemoglobin ratio to predict progression-free survival for patients with locally advanced hepatocellular carcinoma. J Clin Oncol. 2017;35(4 Suppl):463.CrossRef Li X, Xing Y-F, Lin Z-H, et al. Platelet-to-hemoglobin ratio to predict progression-free survival for patients with locally advanced hepatocellular carcinoma. J Clin Oncol. 2017;35(4 Suppl):463.CrossRef
39.
go back to reference Chen XL, Xue L, Wang W, et al. (2015) Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte, and platelet in patients with gastric carcinoma: a retrospective cohort study. Oncotarget. 6:41370–82.PubMedPubMedCentral Chen XL, Xue L, Wang W, et al. (2015) Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte, and platelet in patients with gastric carcinoma: a retrospective cohort study. Oncotarget. 6:41370–82.PubMedPubMedCentral
40.
go back to reference Jiang H, Li H, Li A, et al. (2016) Preoperative combined hemoglobin, albumin, lymphocyte, and platelet levels predict survival in patients with locally advanced colorectal cancer. Oncotarget. 7:72076–83.PubMedPubMedCentral Jiang H, Li H, Li A, et al. (2016) Preoperative combined hemoglobin, albumin, lymphocyte, and platelet levels predict survival in patients with locally advanced colorectal cancer. Oncotarget. 7:72076–83.PubMedPubMedCentral
41.
go back to reference Peng D, Zhang CJ, Gong YQ, et al. (2018) Prognostic significance of HALP (hemoglobin, albumin, lymphocyte, and platelet) in patients with bladder cancer after radical cystectomy. Sci Rep. 8:794.CrossRefPubMedPubMedCentral Peng D, Zhang CJ, Gong YQ, et al. (2018) Prognostic significance of HALP (hemoglobin, albumin, lymphocyte, and platelet) in patients with bladder cancer after radical cystectomy. Sci Rep. 8:794.CrossRefPubMedPubMedCentral
42.
go back to reference Steffens S, Junker K, Roos FC, et al. (2014) Small renal cell carcinomas: how dangerous are they really? Results of a large multicenter study. Eur J Cancer. 50:739–45.CrossRefPubMed Steffens S, Junker K, Roos FC, et al. (2014) Small renal cell carcinomas: how dangerous are they really? Results of a large multicenter study. Eur J Cancer. 50:739–45.CrossRefPubMed
43.
go back to reference Mejean A, Ravaud A, Thezenas S, et al. (2018) Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 379:417–27.CrossRefPubMed Mejean A, Ravaud A, Thezenas S, et al. (2018) Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 379:417–27.CrossRefPubMed
Metadata
Title
The CANLPH Score, an Integrative Model of Systemic Inflammation and Nutrition Status (SINS), Predicts Clinical Outcomes After Surgery in Renal Cell Carcinoma: Data From a Multicenter Cohort in Japan
Authors
Kazumasa Komura, MD, PhD
Takeshi Hashimoto, MD, PhD
Takuya Tsujino, MD
Ryu Muraoka, MD
Takeshi Tsutsumi, MD
Naoya Satake, MD, PhD
Tomohisa Matsunaga, MD
Yuki Yoshikawa, MD
Tomoaki Takai, MD, PhD
Koichiro Minami, MD, PhD
Kohei Taniguchi, MD, PhD
Hirofumi Uehara, MD
Tomohito Tanaka, MD, PhD
Hajime Hirano, MD, PhD
Hayahito Nomi, MD, PhD
Naokazu Ibuki, MD, PhD
Kiyoshi Takahara, MD, PhD
Teruo Inamoto, MD, PhD
Yoshio Ohno, MD, PhD
Haruhito Azuma, MD, PhD
Publication date
01-09-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 9/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07530-5

Other articles of this Issue 9/2019

Annals of Surgical Oncology 9/2019 Go to the issue